Practical Management of Melanoma

  • Mark F. Naylor


Melanoma incidence continues to rise at an alarming rate. More than 62,000 new cases and over 8,000 deaths were predicted for 2008 in the United States.1 Today, approximately one out of every six cancer survivors is a melanoma survivor.1 This chapter presents a broad and practical approach to the subject of treating a patient with suspected or proven melanoma.


Sentinel Node Brain Metastasis Sentinel Node Biopsy Gamma Knife Excisional Biopsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    SEER Cancer Statistics Review, 1975–2005. In, Vol. 2008: National Cancer Institute 2007.Google Scholar
  2. 2.
    Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;92:2771–2776.CrossRefGoogle Scholar
  3. 3.
    Rigel DS, Friedman RJ, Kopf AW, et al. ABCDE—an evolving concept in the early detection of melanoma. Arch Dermatol. 2005;141:1032–1034.PubMedCrossRefGoogle Scholar
  4. 4.
    Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol. 2005;52:109–121.PubMedCrossRefGoogle Scholar
  5. 5.
    Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45:579–586.PubMedCrossRefGoogle Scholar
  6. 6.
    Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol. 1998;134:569–572.PubMedCrossRefGoogle Scholar
  7. 7.
    Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol. 2008.Google Scholar
  8. 8.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648.PubMedGoogle Scholar
  9. 9.
    Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149:66–69.PubMedCrossRefGoogle Scholar
  10. 10.
    Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27–29, 1992. Consensus statement/NIH Consensus Development Conference 1992;10:1–25.Google Scholar
  11. 11.
    Bene NI, Healy C, Coldiron BM. Mohs Micrographic Surgery is Accurate 95.1% of the Time for Melanoma In Situ: A Prospective Study of 167 Cases. Dermatol Surg 2008.Google Scholar
  12. 12.
    Walling HW, Scupham RK, Bean AK, et al. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 2007;57:659–664.PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma: a follow-up study. Dermatol Surg. 1998;24:673–677.PubMedCrossRefGoogle Scholar
  14. 14.
    Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg. 2007;33:395–402.PubMedCrossRefGoogle Scholar
  15. 15.
    Bricca GM, Brodland DG, Ren D, et al. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:92–100.PubMedCrossRefGoogle Scholar
  16. 16.
    Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004;140:1087–1092.PubMedCrossRefGoogle Scholar
  17. 17.
    Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003;110:2011–2018.PubMedCrossRefGoogle Scholar
  18. 18.
    Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003;139:943–944.PubMedCrossRefGoogle Scholar
  19. 19.
    Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151:485–488.PubMedCrossRefGoogle Scholar
  20. 20.
    Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 2008;34:147–151.PubMedCrossRefGoogle Scholar
  22. 22.
    Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008;58:142–148.PubMedCrossRefGoogle Scholar
  23. 23.
    Somach SC, Taira JW, Pitha JV, et al. Pigmented lesions in actinically damaged skin: histopathologic comparison of biopsy and excisional specimens. Arch Dermatol. 1996;132:1297–1302.PubMedCrossRefGoogle Scholar
  24. 24.
    Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in Stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg. 1991;78:1108–1110.PubMedCrossRefGoogle Scholar
  25. 25.
    Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I cutaneous melanoma? J Am Acad Dermatol. 1985;13:983–987.PubMedCrossRefGoogle Scholar
  26. 26.
    Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol. 2002;46:690–694.PubMedCrossRefGoogle Scholar
  27. 27.
    McKenna DB, Lee RJ, Prescott RJ, et al. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision. Br J Dermatol. 2004;150:523–530.PubMedCrossRefGoogle Scholar
  28. 28.
    Gannon CJ, Rousseau DL Jr, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107:2647–2652.PubMedCrossRefGoogle Scholar
  29. 29.
    Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159–1162.PubMedCrossRefGoogle Scholar
  30. 30.
    Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1–4 mm): Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262–267; discussion 7–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 1998;5:322–328.PubMedCrossRefGoogle Scholar
  32. 32.
    McKinnon JG, Starritt EC, Scolyer RA, et al. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg. 2005;241:326–333.PubMedCrossRefGoogle Scholar
  33. 33.
    Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg. 1984;200:759–763.PubMedGoogle Scholar
  34. 34.
    Aitken DR, Clausen K, Klein JP, et al. The extent of primary melanoma excision. A re-evaluation—how wide is wide? Ann Surg. 1983;198:634–641.PubMedCrossRefGoogle Scholar
  35. 35.
    Ackerman AB, Scheiner AM. How wide and deep is wide and deep enough? A critique of surgical practice in excisions of primary cutaneous malignant melanoma. Hum Pathol. 1983;14:743–744.PubMedCrossRefGoogle Scholar
  36. 36.
    Salopek TG, Slade JM, Marghoob AA, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma. J Am Acad Dermatol. 1995;33:451–461.PubMedCrossRefGoogle Scholar
  37. 37.
    Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol. 2001;45:260–276.PubMedCrossRefGoogle Scholar
  38. 38.
    Nestle FO, Kerl H. Melanoma. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. Vol 2. 1st ed. New York, NY: Mosby; 2003:1789–1817.Google Scholar
  39. 39.
    Veronesi U, Adams J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I malignant melanoma of the skin of the lower extremities. Cancer. 1982;49:2420–2430.PubMedCrossRefGoogle Scholar
  40. 40.
    Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627–630.PubMedCrossRefGoogle Scholar
  41. 41.
    Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697–705.PubMedGoogle Scholar
  42. 42.
    Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1–4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263; discussion 63–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Landry CS, McMasters KM, Scoggins CR. The evolution of the management of regional lymph nodes in melanoma. J Surg Oncol. 2007;96:316–321.PubMedCrossRefGoogle Scholar
  44. 44.
    Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am. 2003;83:385–403.PubMedCrossRefGoogle Scholar
  45. 45.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317.PubMedCrossRefGoogle Scholar
  46. 46.
    Rex J, Paradelo C, Mangas C, et al. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases. Dermatol Surg. 2005;31:1385–1393.PubMedCrossRefGoogle Scholar
  47. 47.
    Gutzmer R, Al Ghazal M, Geerlings H, et al. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137–1141.PubMedCrossRefGoogle Scholar
  48. 48.
    Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141:728–735.PubMedCrossRefGoogle Scholar
  49. 49.
    White RR, Tyler DS. Management of node-positive melanoma in the era of sentinel node biopsy. Surg Oncol. 2000;9:119–125.PubMedCrossRefGoogle Scholar
  50. 50.
    Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15:670–673.PubMedCrossRefGoogle Scholar
  51. 51.
    Willis AI, Ridge JA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck. 2007;29:979–985.PubMedCrossRefGoogle Scholar
  52. 52.
    Kilpatrick LA, Shen P, Stewart JH, et al. Use of sentinel lymph node biopsy for melanoma of the head and neck. Am Surg. 2007;73:754–758; discussion 8–9.PubMedGoogle Scholar
  53. 53.
    Morris KT, Stevens JS, Pommier RF, et al. Usefulness of preoperative lymphoscintigraphy for the identification of sentinel lymph nodes in melanoma. Am J Surg. 2001;181:423–426.PubMedCrossRefGoogle Scholar
  54. 54.
    Livestro DP, Kaine EM, Michaelson JS, et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007;110:614–624.PubMedCrossRefGoogle Scholar
  55. 55.
    Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247–258.PubMedCrossRefGoogle Scholar
  56. 56.
    Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449–458.PubMedCrossRefGoogle Scholar
  57. 57.
    Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13:533–541.PubMedCrossRefGoogle Scholar
  58. 58.
    Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617–621.PubMedCrossRefGoogle Scholar
  59. 59.
    Corsetti RL, Allen HM, Wanebo HJ. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol. 2000;7:456–460.PubMedCrossRefGoogle Scholar
  60. 60.
    Cuellar FA, Vilalta A, Rull R, et al. Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res. 2004;14:277–282.PubMedCrossRefGoogle Scholar
  61. 61.
    Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005;18:1232–1242.PubMedCrossRefGoogle Scholar
  62. 62.
    Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109:100–108.PubMedCrossRefGoogle Scholar
  63. 63.
    Morris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15:316–322.PubMedCrossRefGoogle Scholar
  64. 64.
    Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol. 2007;34:509–515.PubMedCrossRefGoogle Scholar
  65. 65.
    Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J (Sudbury, Mass). 2007;13:217–222.CrossRefGoogle Scholar
  66. 66.
    Mendenhall W, Amdur R, Hinerman R, et al. Head and neck mucosal melanoma. Am J Clin Oncol. 2005;28:626–630.PubMedCrossRefGoogle Scholar
  67. 67.
    Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18–26.PubMedCrossRefGoogle Scholar
  68. 68.
    Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313–319.PubMedCrossRefGoogle Scholar
  69. 69.
    Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004;11:1079–1084.PubMedCrossRefGoogle Scholar
  70. 70.
    Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002;20:4555–4558.PubMedCrossRefGoogle Scholar
  71. 71.
    Foote M, Burmeister B, Burmeister E, et al. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg. 2008;78:273–276.PubMedCrossRefGoogle Scholar
  72. 72.
    Elias EG, Zapas JL, Beam SL, et al. Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up. Melanoma Res. 2007;17:310–315.PubMedCrossRefGoogle Scholar
  73. 73.
    Morton DL. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Dev Biol (Basel ). 2004;116:209–217; discussion 29–36.Google Scholar
  74. 74.
    Eilber FR, Morton DL, Holmes EC, et al. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med. 1976;294:237–240.PubMedCrossRefGoogle Scholar
  75. 75.
    Davis-Daneshfar A, Boni R, von Wussow P, et al. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo. J Immunother. 1997;20:208–213.PubMedCrossRefGoogle Scholar
  76. 76.
    Ridolfi L, Ridolfi R, Riccobon A, et al. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother. 2003;26:156–162.PubMedCrossRefGoogle Scholar
  77. 77.
    Gardini A, Ercolani G, Riccobon A, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol. 2004;87:46–52.PubMedCrossRefGoogle Scholar
  78. 78.
    Moschos S, Kirkwood J, Konstantinopoulos P. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004;22:11–14.PubMedCrossRefGoogle Scholar
  79. 79.
    Hancock B, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53–61.PubMedCrossRefGoogle Scholar
  80. 80.
    Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677.PubMedCrossRefGoogle Scholar
  81. 81.
    Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol. 1991;18:83–90.PubMedGoogle Scholar
  82. 82.
    Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006;142:433–438.PubMedCrossRefGoogle Scholar
  83. 83.
    Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol. 2007;46:575–577.PubMedCrossRefGoogle Scholar
  84. 84.
    Francken AB, Shaw HM, Thompson JF. Detection of second primary cutaneous melanomas. Eur J Surg Oncol. 2008;34:587–592.PubMedGoogle Scholar
  85. 85.
    Wood TF, DiFronzo LA, Rose DM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol. 2001;8:658–662.PubMedCrossRefGoogle Scholar
  86. 86.
    Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139:961–966; discussion 6–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Hena MA, Emrich LJ, Nambisan RN, et al. Effect of surgical treatment on stage IV melanoma. Am J Surg. 1987;153:270–275.PubMedCrossRefGoogle Scholar
  88. 88.
    Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983–1991.PubMedCrossRefGoogle Scholar
  89. 89.
    Gutman H, Hess KR, Kokotsakis JA, et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001;25:750–758.PubMedCrossRefGoogle Scholar
  90. 90.
    de Wilt JH, McCarthy WH, Thompson JF. Surgical treatment of splenic metastases in patients with melanoma. J Am Coll Surg. 2003;197:38–43.PubMedCrossRefGoogle Scholar
  91. 91.
    Boogerd W, De Gast G, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306–312.PubMedCrossRefGoogle Scholar
  92. 92.
    Kased N, Huang K, Nakamura J, et al. Gamma knife radiosurgery for brainstem metastases: the UCSF experience. J Neurooncol. 2008;86:195–205.PubMedCrossRefGoogle Scholar
  93. 93.
    Majer M, Samlowski WE. Management of metastatic melanoma patients with brain metastases. Curr Oncol Rep. 2007;9:411–416.PubMedCrossRefGoogle Scholar
  94. 94.
    Samlowski W, Watson G, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109:1855–1862.PubMedCrossRefGoogle Scholar
  95. 95.
    Mathieu D, Kondziolka D, Cooper P, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007;60:471–481; discussion 81–82.PubMedGoogle Scholar
  96. 96.
    Agarwala SS. Relevance and necessity of studies on second-line chemotherapy in melanoma. Onkologie. 2004;27:527–528.PubMedCrossRefGoogle Scholar
  97. 97.
    Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs. 2005;6:1234–1239.PubMedGoogle Scholar
  98. 98.
    Middleton MR, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer. 2000;82:1158–1162.PubMedCrossRefGoogle Scholar
  99. 99.
    Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen vs dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2751.PubMedGoogle Scholar
  100. 100.
    Lawson DH. Choices in adjuvant therapy of melanoma. Cancer Control. 2005;12:236–241.PubMedGoogle Scholar
  101. 101.
    Lorigan P, Eisen T, Hauschild A. Systemic therapy for metastatic malignant melanoma–from deeply disappointing to bright future? Experimental Dermatology. 2008;17:383–394.PubMedCrossRefGoogle Scholar
  102. 102.
    Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005;23:6747–6755.PubMedCrossRefGoogle Scholar
  103. 103.
    Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol. 2006;17:571–577.PubMedCrossRefGoogle Scholar
  104. 104.
    Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl 1):S11–S14.PubMedGoogle Scholar
  105. 105.
    Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008;26:955–962.PubMedCrossRefGoogle Scholar
  106. 106.
    Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25:8505.Google Scholar
  107. 107.
    Comin-Anduix B, Lee Y, Jalil J, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008;6:22.PubMedCrossRefGoogle Scholar
  108. 108.
    Cohn M. What roles do regulatory T cells play in the control of the adaptive immune response? Int Immunol. 2008;20:1107–1118.PubMedCrossRefGoogle Scholar
  109. 109.
    Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008;38:921–924.PubMedCrossRefGoogle Scholar
  110. 110.
    Gallimore A, Godkin A. Regulatory T cells and tumour immunity—observations in mice and men. Immunology. 2008;123:157–163.PubMedCrossRefGoogle Scholar
  111. 111.
    Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26:3445–3455.PubMedCrossRefGoogle Scholar
  112. 112.
    Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.PubMedCrossRefGoogle Scholar
  113. 113.
    Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977.PubMedCrossRefGoogle Scholar
  114. 114.
    Bulanhagui CA, Ribas A, Pavlov D, et al. Phase I clinical trials of ticilimumab: tumor responses are sufficient but not necessary for prolonged survival. J Clin Oncol. 2006;24:8036.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Mark F. Naylor
    • 1
  1. 1.Dermatology Associates of San AntonioSan AntonioUSA

Personalised recommendations